GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

NCT07540390 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-sen University

Phase

Phase 3

Started

2026-05-08

Last updated

2026-04-22

Condition(s) studied

Nasopharyngeal Carcinoma

Investigational drug(s) / intervention(s)

Toripalimab →Anlotinib →Cisplatin →Gemcitabine →radiation

Toripalimab: Toripalimab, 240 mg per administration, on Day 1, diluted in 100 mL of normal saline, administered as an intravenous infusion over 30 minutes (no less than 20 minutes and no more than 60 minutes). After the toripalimab infusion, there should be an interval of 30-60 minutes before administering gemcitabine and cisplatin. Each treatment cycle is 21 days. If the subject's toxicity recovery does not meet the criteria for the next cycle of chemotherapy, the start of the next cycle may be appropriately delayed, but the delay should not exceed 21 days. A total of 9 cycles will be administered.

Anlotinib: Anlotinib, 8 mg per dose per day, once daily on Days 1-14, taken orally before breakfast. Each treatment cycle is 21 days. If the subject's toxicity recovery does not meet the criteria for the next cycle of chemotherapy, the start of the next cycle may be appropriately delayed, but the delay should not exceed 21 days. A total of 3 cycles will be administered.

Cisplatin: Cisplatin, with a treatment cycle of 21 days. If the subject's toxicity recovery does not meet the criteria for the next cycle of chemotherapy, the start of the next cycle may be appropriately delayed, but the delay should not exceed 21 days. A total of 5 cycles will be administered.

Gemcitabine: Gemcitabine, 1000 mg/m², on Days 1 and 8, diluted in 500 mL of 0.9% normal saline, administered as an intravenous infusion. Each treatment cycle is 21 days. If the subject's toxicity recovery does not meet the criteria for the next cycle of chemotherapy, the start of the next cycle may be appropriately delayed, but the delay should not exceed 21 days. A total of 3 cycles will be administered.

radiation: IMRT

Study summary

The investigators have designed a multicenter, open-label, randomized controlled phase III clinical study of GAPP induction therapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy for high-risk locoregionally advanced nasopharyngeal carcinoma (stage III, AJCC 9th edition). The aim is to obtain high-level, high-quality evidence-based data to clarify the efficacy and safety of combining chemoradiotherapy with PD-1 antibody and anlotinib, thereby providing a new treatment strategy to improve the prognosis of patients with high-risk locoregionally advanced nasopharyngeal carcinoma. In this study, GPP induction chemotherapy followed by concurrent chemoradiotherapy and toripalimab maintenance therapy is selected as the control group. This regimen is currently the standard treatment recommended by guidelines for high-risk locoregionally advanced nasopharyngeal carcinoma, with well-established efficacy and broad clinical application. It provides a reliable benchmark for comparing the efficacy and safety of the experimental group, meets ethical requirements, and has mature clinical operational procedures.

Eligibility

Sex

ALL

Min age

18 Years

Max age

65 Years

Healthy volunteers

Inclusion Criteria: * Voluntary participation and signed informed consent. * Age 18-65 years, male or non-pregnant female. * Pathologically confirmed non-keratinizing nasopharyngeal carcinoma (differentiated or undifferentiated type, i.e., WHO type II or III). * Previously untreated patients with no history of other malignancies; initial treatment for nasopharyngeal carcinoma. * Stage III: TanyN3M0 / T4N0-2M0 (9th AJCC/UICC staging system). * ECOG performance status 0-1, with no severe dysfunction of vital organs (heart, lung, liver, kidney, etc.). * Hemoglobin (HGB) ≥90 g/L, white blood cell count (WBC) ≥4.0×10\^9 /L, platelet count (PLT) ≥100×10\^9/L. * Liver function: ALT and AST \<2.5× upper limit of normal (ULN); total bilirubin \<2.0×ULN. * Renal function: serum creatinine \<1.5×ULN. Exclusion Criteria: * Patients with recurrent or distant metastatic nasopharyngeal carcinoma. * Pathologically confirmed keratinizing squamous cell carcinoma (WHO type I). * Receipt of systemic or topical glucocorticoid therapy within 4 weeks prior to enrollment. * Participation in another clinical trial of an investigational drug within 3 months prior to treatment. * Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Patients with idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans), radiation pneumonitis that is clinically symptomatic or requires steroid therapy, active pneumonitis, or other moderate-to-severe pulmonary diseases that significantly affect lung function. * Comorbidities requiring long-term immunosuppressive medication or systemic/topical corticosteroids at immunosuppressive doses. * Prior use of anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibodies (or any other antibodies targeting T-cell co-stimulatory or checkpoint pathways) with documented disease progression at the time of study entry. * Presence of any active autoimmune disease or history of autoimmune disease (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, nephritis). Patients with vitiligo or childhood asthma that has completely resolved and requires no intervention in adulthood may be included; patients requiring bronchodilators for medical management of asthma are excluded. * HIV-positive; HBsAg-positive with detectable HBV DNA copy number (quantitative detection ≥1000 cps/mL); positive hepatitis C antibody (HCV Ab) with detectable HCV RNA. * Receipt of any anti-infective vaccine (e.g., influenza vaccine, varicella vaccine) within 4 weeks prior to enrollment. * Positive pregnancy test in women of childbearing potential, or lactating women. * Inability to comply with scheduled follow-up due to psychological, social, family, or geographical reasons.

Primary outcome measure(s)

3-year progression-free survival — From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years.
3-year progression-free survival

Trial sites (1)

Facility	City	Region	Status
Sun yat-sen university cancer center	Guangzhou	Guangdong

More Sun Yat-sen University trials in China

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma. Active, not recruiting

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL Recruiting

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC Starting soon

BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Enrolling by invitation

Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma Recruiting

Other trials for the same condition

Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma Recruiting

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma Recruiting

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC Starting soon

Radiotherapy Combined With Endostatin and Capecitabine for NPC Recruiting

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07540390 on ClinicalTrials.gov ↗ ← All trials in China